[Prophylaxis of thrombembolic diseases with rivaroxaban].
Gassanov
N
N
Klinik III für Innere Medizin, Herzzentrum der Universität zu Köln, Köln. Natig.Gassanov@uk-koeln.de
Caglayan
E
E
Erdmann
E
E
Er
F
F
D000284:Administration, Oral; D019644:Arthroplasty, Replacement, Hip; D019645:Arthroplasty, Replacement, Knee; D001682:Biological Availability; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D019934:International Normalized Ratio; D008657:Metabolic Clearance Rate / Q000502:physiology; D009025:Morpholines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010314:Partial Thromboplastin Time; D011183:Postoperative Complications / Q000517:prevention & control*; D011485:Protein Binding; D011517:Prothrombin Time; D000069552:Rivaroxaban; D013876:Thiophenes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013923:Thromboembolism / Q000097:blood / Q000517:prevention & control*
D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D009025:Morpholines; D013876:Thiophenes; D000069552:Rivaroxaban